( )
Impressum
Aldevron Freiburg
(formerly Genovac GmbH)
Waltershofener Str. 17
79111 Freiburg
Germany
Phone +49-(0)761-45636-0
Fax: +49-(0)761-45636-29
email: antibody@aldevron.com
Managing Director
Dr. John Thompson
jthompson@aldevron.com
Commercial Register
Local Court Freiburg
Register: HRB 7270
(formerly Genovac GmbH)
Waltershofener Str. 17
79111 Freiburg
Germany
Phone +49-(0)761-45636-0
Fax: +49-(0)761-45636-29
email: antibody@aldevron.com
Managing Director
Dr. John Thompson
jthompson@aldevron.com
Commercial Register
Local Court Freiburg
Register: HRB 7270
VAT-ID No.
DE 813950004
Disclaimer
All information and other data on this website is not binding and subject to the proviso that it may be updated at any time without prior notice. Liability for the accuracy and completeness of this information shall, therefore, be excluded.
Linked webpages/ websites exclusively contain third party information that is beyond our control. We shall assume no responsibility for the contents of the linked webpages/ websites of third parties.
Links on third party websites to our website are only permitted if made to our home page. An integration of our webpages/ website into third party websites (e.g. by means of "Framing" etc.) is not permitted.
DE 813950004
Disclaimer
All information and other data on this website is not binding and subject to the proviso that it may be updated at any time without prior notice. Liability for the accuracy and completeness of this information shall, therefore, be excluded.
Linked webpages/ websites exclusively contain third party information that is beyond our control. We shall assume no responsibility for the contents of the linked webpages/ websites of third parties.
Links on third party websites to our website are only permitted if made to our home page. An integration of our webpages/ website into third party websites (e.g. by means of "Framing" etc.) is not permitted.
“This website uses Google Analytics, a web analytics service provided by Google, Inc. (“Google”). Google Analytics uses “cookies”, which are text files placed on your computer, to help the website analyze how users use the site. The information generated by the cookie about your use of the website (including your IP address) will be transmitted to and stored by Google on servers in the United States . Google will use this information for the purpose of evaluating your use of the website, compiling reports on website activity for website operators and providing other services relating to website activity and internet usage. Google may also transfer this information to third parties where required to do so by law, or where such third parties process the information on Google's behalf. Google will not associate your IP address with any other data held by Google. You may refuse the use of cookies by selecting the appropriate settings on your browser, however please note that if you do this you may not be able to use the full functionality of this website. By using this website, you consent to the processing of data about you by Google in the manner and for the purposes set out above.” (Extract from Google Analytics data protection act, Chapter 8)
As of July 1, 2011 GENOVAC has officially changed it's name to Aldevron Freiburg. The core team and technologies will remain intact. Representing the antibody arm of Aldevron, Aldevron Freiburg will continue being a world leader in genetic immunization utilizing GENOVAC Antibody Technology™.
GENOVAC product and services have been migrated to the Aldevron website and are available at aldevron.com/genovac. If you have any questions, please do not hesitate to contact Aldevron.
GENOVAC product and services have been migrated to the Aldevron website and are available at aldevron.com/genovac. If you have any questions, please do not hesitate to contact Aldevron.
On January 1, 2004 GENOVAC became a part of Aldevron LLC, USA. Both companies have specialized in the area of genetic immunization to develop antibodies. The combined expertise and clientele continue to strengthen Aldevron as a world-leader in antibody technology.
